Progress Adult Study

The HIV Netherlands Australia Thailand Research Collaboration5,600 enrolled

Overview

The purpose of this study is to study the HIV disease progression in HIV-infected Thai Adult.

This is a multicenter, observational prospective cohort study. All HIV-infected patients from Bamrasnaradura Institute, Sanpatong Hospital and HIV-NAT, Thai Red Cross AIDS Research Centre, are followed to assess HIV disease progression.

Study Type

OBSERVATIONAL

Enrollment

5,600

Conditions

HIV Depression

Interventions

standard regimens according to the Thai Ministry of Public Health national guidelinesDRUG

Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. There is evidence that HIV infection true (blood positive results by ELISA (ELISA) has been confirmed or detected evidence co-infection. HIV in the body by PCR, HIV-RNA PCR).Currently on PI regimens 2. Signed consent form 3. Age\> 18 years Exclusion Criteria: 1. Patients who came for treatment in a department other than out patient, such as inpatient or emergency room. 2. Patients are not willing to receive treatment on a regular basis in all 3 hospitals as patients normally receive treatment at other hospitals on a regular basis. However, due to urgent events. Need to receive treatment in hospital and three of. 3. Patients who have been diagnosed by doctors as a Psychological disorder that can not store the data. 4. Patients who have been diagnosed by a medical condition that Alcoholism

Locations (3)

Bamrasnaradura infectious disease institute

Nonthaburi, Changwat Nonthaburi, Thailand

Sanpatong Hospital

Chiang Mai, Chiang Mai, Thailand

HIV-NAT, Thai Red Cross AIDS Research Centre

Bangkok, Thailand

Outcomes

Primary Outcomes

HIV related adverse events

Time until patient has HIV related adverse events

Time frame: 1 year

Secondary Outcomes

Immunological failure

time to immunological failure

Time frame: 1 year

virological failure

time to virological failure

Time frame: 1 year

the change of quality of life

time to change of quality of life

Time frame: 1 year

depression

time when patient develops depression

Time frame: 1 year

genotypic resistance

time to developing genotypic resistance

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.